Drug Profile
Research programme: heat shock protein 90 inhibitors - Vernalis
Alternative Names: CCT 018159; CCT 066950; CCT 066952; CCT 066963; CCT 066965; NVP-BEP795; RBT 0028535; VER 49009Latest Information Update: 09 Apr 2021
Price :
$50
*
At a glance
- Originator Cancer Research Technology; The Institute of Cancer Research; Vernalis
- Developer Novartis; Vernalis
- Class Pyrazoles
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Europe (IV)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Europe (PO)